PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3178239-3 1988 The KFr cell line proved to be 3.1-fold resistant to L-phenylalanine mustard (L-PAM). Melphalan 53-76 peptidylglycine alpha-amidating monooxygenase Homo sapiens 80-83 3182309-3 1988 Patients with previously untreated myeloma received 12 weeks of melphalan (L-PAM) and prednisone (pred) therapy. Melphalan 64-73 peptidylglycine alpha-amidating monooxygenase Homo sapiens 77-80 6541216-2 1984 A single dose of cisplatin (1 mg/kg) enhanced the in vivo tumor killing by melphalan (L-PAM; 8 mg/kg). Melphalan 75-84 peptidylglycine alpha-amidating monooxygenase Homo sapiens 88-91 3349564-1 1988 A sensitive high-performance liquid chromatographic assay has been developed for the measurement of the alkylating cytostatic drug melphalan (4-[bis(2-chloroethyl)amino]-L-phenyl-alanine, or L-phenylalanine-mustard, L-PAM) and its two hydrolysis products, monohydroxy melphalan (MOH) and dihydroxy melphalan (DOH). Melphalan 131-140 peptidylglycine alpha-amidating monooxygenase Homo sapiens 218-221 3497748-1 1987 In vitro treatment with melphalan (L-PAM, L-phenylalanine mustard), 2 micrograms/2 X 10(6) cells, significantly decreased the total number of E-rosette-positive (E+) T lymphocytes from peripheral blood (PBL) of healthy human donors as well as those of the OKT4 (precursor suppressor/helper/inducer T cells) and OKT17 populations (suppressor cells within the OKT4 subset). Melphalan 24-33 peptidylglycine alpha-amidating monooxygenase Homo sapiens 37-40 6434498-1 1984 CB 1954 potentiates the cytotoxic action of the bifunctional alkylating agent melphalan (L-PAM). Melphalan 78-87 peptidylglycine alpha-amidating monooxygenase Homo sapiens 91-94 7000345-0 1980 L-phenylalanine mustard (L-PAM): the first 25 years. Melphalan 0-23 peptidylglycine alpha-amidating monooxygenase Homo sapiens 27-30 6546359-1 1984 Melphalan (L-PAM) was compared to (C) cyclophosphamide, (M) methotrexate, and (F) 5-fluorouracil (CMF) in 413 patients with advanced ovarian carcinoma. Melphalan 0-9 peptidylglycine alpha-amidating monooxygenase Homo sapiens 13-16 6882665-1 1983 Misonidazole (MISO) given as a large single dose enhanced the action of cyclophosphamide (Cy) and melphalan (L-PAM) in two mouse tumours. Melphalan 98-107 peptidylglycine alpha-amidating monooxygenase Homo sapiens 111-114 101843-1 1978 A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. Melphalan 32-41 peptidylglycine alpha-amidating monooxygenase Homo sapiens 45-48 536450-1 1979 A procedure for the separation and quantitation of melphalan (L-PAM) and its hydrolysis products by high-performance liquid chromatography is described. Melphalan 51-60 peptidylglycine alpha-amidating monooxygenase Homo sapiens 64-67 11878777-2 2001 Buthionine sulfoximine (BSO) can deplete glutathione and synergistically enhance in vitro sensitivity to the alkylating agent melphalan (L-PAM) for many neuroblastoma cell lines, but optimal use of this combination needs to be defined because clinical responses have been less frequent and not durable. Melphalan 126-135 peptidylglycine alpha-amidating monooxygenase Homo sapiens 139-142 25621797-2 2015 Here, we report on 41 HL patients with active disease after salvage therapy and who received high-dose melphalan (HD-PAM) and auto-SCT as a bridge to a second autologous or an allogeneic transplantation between 2002 and 2013 at our center. Melphalan 103-112 peptidylglycine alpha-amidating monooxygenase Homo sapiens 117-120 21042310-1 2011 We evaluated the efficacy and safety of the conditioning regimen that consisted of TBI and melphalan (L-PAM), followed by hematopoietic SCT (HSCT) in 23 children with advanced hematological malignancies. Melphalan 91-100 peptidylglycine alpha-amidating monooxygenase Homo sapiens 104-107 18999930-2 2008 In this paper, we report on the modification of the anticancer drugs, methotrexate (MTX) and melphalan (L-PAM), covalently linked to PEGs for drug delivery. Melphalan 93-102 peptidylglycine alpha-amidating monooxygenase Homo sapiens 106-109 17176891-0 2006 [Cryotherapy is useful and safe in the prevention of oral mucositis after high-dose melphalan (L-PAM)]. Melphalan 84-93 peptidylglycine alpha-amidating monooxygenase Homo sapiens 97-100 12189530-0 2002 Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Melphalan 71-80 peptidylglycine alpha-amidating monooxygenase Homo sapiens 84-87 1016968-4 1976 Melphalan (L-PAM) inhibits nucleic-acid synthesis but not protein synthesis in L1210/0 and L1210/CPA. Melphalan 0-9 peptidylglycine alpha-amidating monooxygenase Homo sapiens 13-16 14761920-1 2004 BACKGROUND: Melphalan (L-PAM) hyperthermic isolated limb perfusion (HILP) is currently considered the standard treatment for patients with in-transit metastases from cutaneous melanoma. Melphalan 12-21 peptidylglycine alpha-amidating monooxygenase Homo sapiens 25-28 9951688-1 1998 Resistance of myeloma cells to melphalan (L-PAM) is a serious problem. Melphalan 31-40 peptidylglycine alpha-amidating monooxygenase Homo sapiens 44-47 11079271-1 2000 The use of high-dose melphalan (L-phenyalalanine mustard or L-PAM) has been shown to be associated with both hematological and non-hematological toxicity. Melphalan 21-30 peptidylglycine alpha-amidating monooxygenase Homo sapiens 62-65 10789721-1 2000 A phase I dose-escalation study was performed to determine whether isolated hepatic perfusion (IHP) with melphalan (L-PAM) allows exposure of the liver to much higher drug concentrations than clinically achievable after systemic administration and leads to higher tumour concentrations of L-PAM. Melphalan 105-114 peptidylglycine alpha-amidating monooxygenase Homo sapiens 118-121 10789721-1 2000 A phase I dose-escalation study was performed to determine whether isolated hepatic perfusion (IHP) with melphalan (L-PAM) allows exposure of the liver to much higher drug concentrations than clinically achievable after systemic administration and leads to higher tumour concentrations of L-PAM. Melphalan 105-114 peptidylglycine alpha-amidating monooxygenase Homo sapiens 291-294 9679558-4 1998 Phase I clinical trials of BSO + melphalan (L-PAM)have been carried out and observed little toxicity with BSO alone and increased myelosuppression with BSO + L-PAM. Melphalan 33-42 peptidylglycine alpha-amidating monooxygenase Homo sapiens 46-49 9679558-4 1998 Phase I clinical trials of BSO + melphalan (L-PAM)have been carried out and observed little toxicity with BSO alone and increased myelosuppression with BSO + L-PAM. Melphalan 33-42 peptidylglycine alpha-amidating monooxygenase Homo sapiens 160-163 9670271-2 1998 In this overview we present our experimental and clinical results with mitomycin C (MMC) and melphalan (L-Pam). Melphalan 93-102 peptidylglycine alpha-amidating monooxygenase Homo sapiens 106-109 9548610-6 1998 Because alkylating agents generally have steep dose-response curves, mitomycin C (MMC) and melphalan (L-PAM) entered phase I/II studies on IHP. Melphalan 91-100 peptidylglycine alpha-amidating monooxygenase Homo sapiens 104-107 2260990-0 1990 Enhancement of melphalan (L-PAM) toxicity by reductive metabolites of 1-methyl-2-nitroimidazole, a model nitroimidazole chemosensitizing agent. Melphalan 15-24 peptidylglycine alpha-amidating monooxygenase Homo sapiens 28-31 9516845-0 1997 Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. Melphalan 54-63 peptidylglycine alpha-amidating monooxygenase Homo sapiens 67-70 9516845-1 1997 Buthionine sulphoximine (BSO) selectively inhibits glutathione (GSH) synthesis and may enhance the antineuroblastoma activity of melphalan (L-PAM). Melphalan 129-138 peptidylglycine alpha-amidating monooxygenase Homo sapiens 142-145 9329556-1 1997 Dramatic clinical results have been obtained in malignant melanoma and sarcoma using hyperthermic limb perfusion in combination with tumor necrosis factor (TNF) and melphalan (L-PAM). Melphalan 165-174 peptidylglycine alpha-amidating monooxygenase Homo sapiens 178-181 7622292-2 1995 The cell-cycle phase perturbations induced by the drug were investigated and compared with those caused by melphalan (L-PAM) in SW626 human ovarian-cancer cells. Melphalan 107-116 peptidylglycine alpha-amidating monooxygenase Homo sapiens 120-123 8004757-4 1994 The addition of each of the modulator combinations for 1 h or 24 h to treatment with melphalan (L-PAM) or carmustine (BCNU) resulted in greater-than-additive cytotoxicity with each of four regimens. Melphalan 85-94 peptidylglycine alpha-amidating monooxygenase Homo sapiens 98-101 2208589-1 1990 Previous studies have demonstrated that three cancer chemotherapeutic compounds of the nitrogen mustard class, melphalan (L-PAM), nitrogen mustard (HN2) and chlorambucil (CBC), each generated DNA lesions that prematurely terminate in vitro transcription. Melphalan 111-120 peptidylglycine alpha-amidating monooxygenase Homo sapiens 124-127